Trehalose

Summary

Trehalose (CHEMBL1236395) is an approved oligosaccharide geroprotector; indicated across 7 conditions including bipolar disorder and acute coronary syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Oligosaccharide
• Indications: 7 conditions
• Clinical trials: 18
• Chemistry: 342.3 Da · C12H22O11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1236395
Name	Trehalose
Type	Oligosaccharide
Max phase	3
FDA approved	yes
PubChem CID	7427
ChEBI	CHEBI:16551
Molecular formula	C12H22O11
Molecular weight	342.3
InChIKey	HDTRYLNUVZCQOY-LIZSDCNHSA-N

SMILES: C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)O

IUPAC name: (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol

ChEBI definition: A trehalose in which both glucose residues have α-configuration at the anomeric carbon.

Pharmacological roles (ChEBI): geroprotector.

Other ChEBI roles (chemical / environmental): human metabolite, Saccharomyces cerevisiae metabolite, Escherichia coli metabolite, mouse metabolite.

Also known as: .alpha., .alpha.-trehalose, Cabaletta, Mushroom sugar, Mycose, NSC-2093, Trehalose, trehalose, Alpha, alpha-trehalose, TREHALOSE

Parent form; salt/anhydrous children: CHEMBL3188936

Patent coverage: 93,984 distinct patent families (281,406 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Trehalose-binding lipoprotein LpqY.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bipolar disorder	3	MONDO:0004985	MONDO:0004985
acute coronary syndrome	2	MONDO:0005542	EFO:0005672
metabolic dysfunction-associated steatotic liver disease	2	MONDO:0013209	EFO:1001248
Machado-Joseph disease	2	MONDO:0007182	Orphanet:98757
amyotrophic lateral sclerosis	2	MONDO:0004976	MONDO:0004976
oculopharyngeal muscular dystrophy	2	MONDO:0008116	MONDO:0008116
Alzheimer disease	1	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
Not specified	7
PHASE4	3
PHASE2	3
PHASE3	1
PHASE2/PHASE3	1
PHASE1/PHASE2	1
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04704518	PHASE4	COMPLETED	Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratectomy
NCT05355064	PHASE4	UNKNOWN	Efficacy of Oral Administration of Trehalose in Patients With Parkinson Disease
NCT05990712	PHASE4	UNKNOWN	The Effect of a Pre-cataract Surgical Ocular Hygiene Regime on Microbial Load, Tear Osmolarity, Dry Eye, and Inflammatory Markers
NCT04297683	PHASE2/PHASE3	RECRUITING	HEALEY ALS Platform Trial - Master Protocol
NCT02800161	PHASE3	COMPLETED	Trehalose as add-on Therapy in Bipolar Depression
NCT07263880	PHASE1/PHASE2	NOT_YET_RECRUITING	Clostridium Butyricum in Stenosing Crohn’s Desease
NCT02015481	PHASE2	COMPLETED	Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients
NCT03700424	PHASE2	UNKNOWN	Inflammation Reduction by TREhalose AdminisTration
NCT04226924	PHASE2	WITHDRAWN	Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose
NCT04663854	PHASE1	UNKNOWN	Mycose AdminiStration for HealIng Alzheimer NEuropathy (MASHIANE)
NCT05593549	EARLY_PHASE1	RECRUITING	Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
NCT07539194	Not specified	RECRUITING	Evaluation of the Performance and Safety of a Single-dose Hyaluronic Acid (Promovia Hydro Balance) in the Treatment of Non-traumatic Degenerative Meniscus Tears
NCT01575288	Not specified	COMPLETED	Oral Trehalose Therapy to Reverse Arterial Aging in Middle-Aged and Older Adults
NCT01745523	Not specified	COMPLETED	Use of a Synthetic Macromolecule (Hydroxypropyl Cellulose ) and Trehalose as Additives for Oocyte Vitrification
NCT03738358	Not specified	COMPLETED	Clinical Study of 12-week Trehalose Intake in Patients With Fatty Liver Disease
NCT04399265	Not specified	UNKNOWN	Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3
NCT04426149	Not specified	COMPLETED	Clinical Effects of Oral Trehalose In Patients With Spinocerebellar Ataxia 3
NCT05597436	Not specified	NO_LONGER_AVAILABLE	Intermediate-Sized Expanded Access Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).